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hepatocellular carcinoma. Preventive modalities are absent and
the current antiviral treatment is limited by resistance, toxicity,
and high costs. Viral entry is required for initiation, spread, and
maintenance of infection, and thus is a promising target for anti-
viral therapy. HCV entry is a highly orchestrated process involv-
ing viral and host cell factors. These include the viral envelope
glycoproteins E1 and E2, CD81, scavenger receptor BI, and tight
junction proteins claudin-1 and occludin. Recent studies in pre-
clinical models and HCV-infected patients have demonstrated
that the virus has developed multiple strategies to escape host
immune responses during viral entry. These include evasion from
neutralizing antibodies and viral spread by cell–cell transmission.
These challenges have to be taken into account for the design of
efﬁcient antiviral strategies. Thus, a detailed understanding of the
mechanisms of viral entry and escape is a prerequisite to deﬁne
viral and cellular targets and develop novel preventive and ther-
apeutic antivirals. This review summarizes the current knowl-
edge about the molecular mechanisms of HCV entry into
hepatocytes, highlights novel targets and reviews the current
preclinical and clinical development of compounds targeting
entry. Proof-of-concept studies suggest that HCV entry inhibitors
are a novel and promising class of antivirals widening the preven-
tive and therapeutic arsenal against HCV infection.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Hepatitis C virus (HCV) is a major cause of chronic hepatitis
worldwide. The current therapy against HCV infection, consisting
of an association of pegylated interferon alpha (PEG-IFN) andJournal of Hepatology 20
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Although the clinical development of novel antivirals targeting
HCV protein processing has been shown to improve sustained
virological response, toxicity of the individual compounds and
development of viral resistance remain major challenges [1–3].
To date, a vaccine is not available. The absence of preventive
strategies is a major limitation for patients undergoing liver
transplantation (LT) for HCV-related end-stage liver disease. Re-
infection of the graft is universal and characterized by accelerated
progression of liver disease [4]. Moreover, treatment of recurrent
HCV infection after LT is challenging due to enhanced adverse
effects and limited efﬁcacy of IFN-based therapies in LT recipients
[4,5]. Recurrent HCV liver disease in the graft with poor outcome
has become an increasing problem faced by hepatologists and
transplant surgeons. Thus, novel antiviral preventive and thera-
peutic strategies are urgently needed.
Viral entry is the ﬁrst step of virus–host cell interactions lead-
ing to productive infection and thus represents an interesting tar-
get for antiviral therapy. HCV entry is believed to be a highly
orchestrated process involving several viral and host cell factors,
thereby offering multiple novel targets for antiviral therapy.
However, multiple strategies evolved by the virus in order to
escape the host immune system, such as escape from neutralizing
antibodies and direct cell–cell transmission, have to be taken into
account for the design of efﬁcient novel antiviral strategies.
Understanding the mechanisms of viral entry and escape is thus
a prerequisite to deﬁne the viral and cellular targets that will give
broad protection against HCV infection.
HCV is an enveloped single-strand RNA virus that mainly tar-
gets hepatocytes. Due to the difﬁculty to grow HCV in vitro and
the species speciﬁcity of this virus, surrogate model systems have
been developed to study HCV entry into hepatocytes: recombi-
nant envelope glycoproteins [6], HCV-like particles (HCV-LP)
[7], HCV pseudo-particles (HCVpp) [8,9] and recombinant infec-
tious HCV (HCVcc) [10–12] have been used to study the interac-
tions of the viral envelope with human hepatoma cells or primary
human hepatocytes. Moreover, the use of transgenic immunode-
ﬁcient mice with hepatocyte-lethal phenotype (Alb-uPA/SCID
[13] and Fah/Rag2/IL2rc mice [14]), that can be successfully
transplanted with primary human hepatocytes, allowed to estab-
lish a small animal model to study certain aspects of HCV infec-
tion in vivo [15,16].
Using the above described model systems, tremendous
progress has been made over the past years in deciphering the11 vol. 54 j 566–576
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mechanisms of HCV-host interactions leading to viral entry. The
understanding of these mechanisms has allowed researchers to
identify novel targets for antivirals, and several compounds are
reaching early clinical development. The aim of this review is to
summarize the current knowledge on the complex mechanisms
of HCV entry into host cells, aswell as to highlight the antiviral tar-
gets and to reviewthecurrentdevelopmentofHCVentry inhibitors
that represent a novel important class of antivirals. Developing
efﬁcient HCV entry inhibitors may hold great promises to improve
the sustained virological response in chronic HCV-infected
patients and thus prevent HCV re-infection during LT.Hepatitis C virus evades host immune responses to enter the
hepatocyte
Viral entry is the ﬁrst step of HCV infection that requires interac-
tion of the HCV envelope glycoproteins E1 and E2 and the host
cell membrane. E1 and E2 are type I transmembrane proteins
with an N-terminal ectodomain and a short C-terminal trans-
membrane domain (TMD). Functional virion-associated E1E2
envelope glycoproteins mediating viral entry form large covalent
complexes stabilized by disulﬁde bridges [17]. The TMD plays a
major role in the biogenesis of the E1E2 complexes and mem-
brane fusion process [18]. The N-terminal ectodomains of E1
and E2 are heavily glycosylated. The glycans play a major role
in E1E2 folding as well as HCV entry [19] and are of crucial
importance for the evasion from the host immune responses by
masking immunogenic envelope epitopes [20]. Moreover, HCV
exists in heterogenous forms in human serum and may be asso-
ciated with VLDL, LDL, and HDL [21–24] also shielding the virus
from neutralizing antibodies targeting the HCV envelope
glycoproteins.Journal of Hepatology 201Both E1 and E2 contain putative fusion domains [25,26].
While the role of E1 in HCV entry is not completely understood,
several E2 domains play pivotal roles in viral entry, i.e. putative
domain binding to two HCV entry factors, CD81 and scavenger
receptor class B type I (SR-BI), and escape from host immune
responses. Hypervariable regions (HVR) have been identiﬁed in
E2. The ﬁrst 27 amino acids of E2 called hypervariable region 1
(HVR1), are the most divergent among HCV isolates. HVR1 plays
an important role in viral ﬁtness, likely due to an involvement in
SR-BI-mediated entry [27], assembly and release of virus particles
[28] as well as HCV membrane fusion process [28]. HVR1 is a tar-
get for neutralizing antibodies. However, due to its high variabil-
ity, antibodies targeting HVR1 exhibit poor cross-neutralization
potency across different HCV isolates [29]. Broadly neutralizing
antibodies are directed against conserved conformational epi-
topes within E2 [30,31] and mostly inhibit E2–CD81 interaction
[32]. The region located immediately downstream of HVR1 con-
tains a potent and highly conserved epitope. This epitope deﬁned
by the mouse monoclonal antibody (mAb) AP33 and a rat mAb
3/11, is involved in E2–CD81 [33] and E2-heparan sulfate interac-
tion [34]. Importantly, mutated variants that escape from AP33
neutralization show very low infectivity [35]. Recently, new con-
formational and conserved epitopes were identiﬁed in the N-ter-
minal part of E2. Antibodies targeting these epitopes neutralize
genetically diverse HCV isolates and protect against heterologous
HCV quasispecies challenge in the human liver-chimeric Alb-
uPA/SCID mouse model [31]. Since these epitopes are thought
to be involved in HCV entry, viral mutation could induce escape
from broadly neutralizing antibodies but at a substantial cost in
viral ﬁtness [35]. The conserved nature of these epitopes makes
them of interest for vaccine and immunotherapeutic
development.
In vivo, humoral responses are thought to play an important
role in controlling HCV infection. Indeed, spontaneous resolvers
tend to have an early induction of neutralizing antibody
responses, whereas chronically evolving subjects have a delayed
initiation of neutralizing antibody responses [36–38]. Further-
more, the generation of cross-reactive humoral responses is asso-
ciated with protection against HCV re-infection [39]. These data
suggest that protective immunity following HCV infection is pos-
sible and highlights the plausibility of preventive antiviral strat-
egies including a vaccine [39]. However, the accelerated
evolution [40] and the diversity of HCV, as well as the variety
of strategies the virus evolved to escape antibody-mediated neu-
tralization (reviewed in [41]), are a major challenge. Indeed, due
to its very high replication rate and the highly error prone viral
polymerase, HCV circulates as a pool of genetically distinct but
closely related variants known as viral quasi-species. The capac-
ity of HCV to mutate continuously allows a high plasticity, an
ability of the virus to adapt to variable environmental conditions
and escape the host’s immune responses leading to HCV persis-
tence [42,43]. Noteworthy, a recent longitudinal analysis of six
HCV-infected patients undergoing LT suggests that efﬁcient entry
and escape from host neutralizing antibodies represent impor-
tant mechanisms for the selection of HCV during LT [43]. As
strains selected during LT could be neutralized by broadly neu-
tralizing antibodies, the major challenge for developing efﬁcient
antiviral strategies targeting the HCV envelope glycoproteins will
be to identify epitopes largely conserved among genotypes and
selected isolates.1 vol. 54 j 566–576 567
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Hepatitis C virus uses multiple host factors to enter its target
cell
HCV attachment and entry into host cells is a complex and mul-
tistep process. Using various model systems, several cell surface
molecules have been identiﬁed to interact with HCV. These
include CD81 [44], the LDL receptor [21], highly sulfated heparan
sulfate (HS) [45], SR-BI [46], DC-SIGN (dendritic cell-speciﬁc
intercellular adhesion molecule three grabbing non integrin)
/L-SIGN (DC-SIGNr, liver and lymph node speciﬁc) [47,48], clau-
din-1 (CLDN1) [49], and occludin (OCLN) [50–52].
In vivo, HCV enters the liver through the sinusoidal blood. Cap-
ture of circulating HCV particles by liver sinusoidal cells may thus
facilitate the viral infection of neighbouring hepatocyteswhich are
not in direct contact with circulating blood. This process may be
mediated by DC-SIGN, which is expressed in Kupffer cells that
localize close to liver sinusoidal endothelial cells (LSEC) and hepa-
tocytes [53], and L-SIGN that is highly expressed in LSEC. DC-SIGN
and L-SIGN have been shown to bind envelope glycoprotein E2
with high afﬁnity [47,54]. On hepatocytes, HS glycosaminoglycans
represent ﬁrst attachment sites [34,45,55] that may help to con-
centrate the virus on the target cell surface and allow further inter-
actions with other host factors triggering viral entry.
CD81 is a ubiquitously expressed 25 kDa tetraspanin, contain-
ing a small extracellular and a large extracellular loop (LEL).
CD81 has been the ﬁrst molecule described to interact with a solu-
ble truncated form of HCV E2 and to be a critical host cell factor for
viral entry [11,56,57]. The LEL seems to play an important role in
this process, as soluble recombinants forms of CD81 LEL have been
shown to inhibit HCVpp and HCVcc infections [58]. Several amino
acid residues critical for E2–CD81 binding have been identiﬁed
throughout the CD81 LEL and HCV E2 [33,44,59–61]. In recent
years, studies using HCVpp and HCVcc have provided additional
valuable information about E2–CD81 interactions and highlighted
the importance of E2 residues at positions 415, 420, 527, 529, 530,
and 535 [62,63] for virus particle–CD81 interaction.
Human SR-BI or CLA-1 (CD36 and LIMPII Analogous-1) is an
82 kDa glycoprotein with a large extracellular loop highly
expressed in the liver and steroidogenic tissues [64]. SR-BI binds
a variety of lipoproteins (HDL, LDL, oxLDL) and is involved in bi-
directional cholesterol transport at the cell membrane. The SR-BI
extracellular loop has been demonstrated to interact with E2
HVR1 [46]. Recent evidence suggests that amino acids 70–87 and
the single residue E210 of SR-BI are required for E2 recognition
[65]. SR-BI may play a dual role during the HCV entry process, dur-
ing both binding and post-binding steps [65,66]. Physiological SR-
BI ligands have been shown tomodulateHCV infection: HDL is able
to enhance HCVpp and HCVcc infections [67,68] whereas oxidized
LDL inhibits HCVpp and HCVcc infections [69]. Interestingly, high
concentrations of HDL and LDL inhibitedHCV replication in human
hepatocytes infected with serum-derived HCV [70]. Moreover,
using serum-derived HCV, it has been suggested that the virus-
associated lipoproteins rather than the E2 protein interact with
SR-BI in transfected CHO cells [71]. A recent mapping study
reported that HCV and HDL binding to SR-BI as well as the lipid
transfer properties of SR-BI are required for SR-BI function as an
HCV entry factor [72]. This study also suggests that the C-terminal
cytoplasmic tail of SR-BI modulates the basal HCV entry process,
but does not seem to inﬂuence HDL-mediated infection-enhance-
ment whereas the extracellular domain is required for E2 binding
and lipid transfer function [72]. Taken together, these results sug-568 Journal of Hepatology 201gest that HCV entry requires the existence of a complex interplay
between lipoproteins, SR-BI, and HCV envelope glycoproteins that
all need to be taken into account for the development of antivirals
targeting SR-BI.
CLDN1, a 23 kDa four transmembrane protein, has been iden-
tiﬁed as a critical HCV hepatocyte entry factor by expression
cloning [49]. Interestingly, CLDN6 and CLDN9 are also able to
mediate HCV entry in hepatoma cells [73,74]. CLDNs are critical
components of tight junctions (TJ) regulating paracellular perme-
ability and polarity. CLDN1 is expressed in all epithelial tissues
but predominantly in the liver [75]. Of note, CLDN1 may localize
to TJ of hepatocytes but also to the basolateral surfaces of these
cells [76]. Recent studies suggest that non-junctional CLDN1
may be involved in HCV entry [49,77] probably during a post-
binding step [49,78]. So far, no direct HCV–CLDN1 interaction
has been demonstrated [49,78]. Mapping studies suggest that
the ﬁrst extracellular loop (ECL1), and more particularly residues
in the highly conserved claudin motif W(30)–GLW(51)–C(54)–
C(64), are critical for HCV entry [49,77]. CLDN1 associates to
CD81 in a variety of cell types and the formation of CLDN1–
CD81 complexes is essential for HCV infection [79,80]. Mutations
at residues 32 and 48 in CLDN1 ECL1 ablate the association with
CD81 and the viral receptor activity [80].
OCLN has been identiﬁed as another host cell factor critical for
HCV entry, probably at a late post-binding event [50,51,81]. OCLN
is a 65 kDa four transmembrane protein expressed in TJ of polar-
ized cells. To date, there is no evidence of a direct interaction
with HCV. It is worth noting that OCLN has been reported to be
one of the two HCV host entry factors responsible for the species
speciﬁcity of HCV: expression of human OCLN and human CD81
may confer HCV permissivity to mouse cell lines [50]. The spe-
cies-speciﬁc determinants of this protein have been mapped to
the second extracellular loop [50]. Interestingly, OCLN expression
on hepatocytes as well as HCV entry is increased upon glucocor-
ticoid treatment [82] while OCLN expression is down-regulated
upon HCV infection to prevent super-infection [51]. Further stud-
ies are needed to decipher the interplay between HCV, OCLN, and
the other known host factors.
As HCV circulates in the blood in association with LDL and
VLDL, the LDL receptor has also been proposed as an attachment
and/or entry factor for HCV [21,83]. As HCVpp are not associated
with lipoproteins, studies investigating the role of LDLR in HCVpp
entry did not show a major role for LDLR [8]. Moreover, no direct
interaction between envelope glycoprotein E2 and LDL or LDLR
was demonstrated [83]. However, the LDLR has been shown to
mediate the internalization of serum-derived HCV into CD81-
deﬁcient HepG2 cells by binding virus-LDL particles [21]. This
will have to be taken into account for the development of antivi-
ral therapies targeting HCV host factors.HCV entry is a multistep process
In vivo, HCVmost likely ﬁrst interactswith the basolateral surfaces
of hepatocytes. HS glycosaminoglycans represent ﬁrst attachment
sites [34,45,55] before the virus interacts with several entry fac-
tors, SR-BI [27,46,66,68,84], CD81 [44,55], CLDN1 [49,78], and
OCLN [50–52] (Fig. 1). It is worth noting that all these entry factors
are required for productive HCV infection. This suggests that HCV
entry may be mediated through the formation of a tightly orches-
tratedHCV-entry factor complex at the plasmamembrane [66,78].1 vol. 54 j 566–576
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First evidence for such co-entry factor complexes has been pro-
vided by ﬂuorescence resonance energy transfer (FRET) studies
demonstrating the role of CLDN1–CD81 complexes in HCV infec-
tion [79,80]. The fact that only members of the CLDN family sup-
porting HCV entry, i.e. CLDN1, CLDN6, and CLDN9, were able to
formcomplexeswithCD81suggests thatCLDN–CD81complex for-
mation is essential for HCV entry [78,80]. To date, our knowledge
about themolecularmechanisms of potential other co-factor asso-
ciation(s) is still rudimental. First studies showed that themajority
of CLDN1proteins at theplasmamembrane interactwithOCLNbut
did not show any relationship between CLDN1–OCLN associationFig. 1. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets f
neutralizing antibodies and other entry inhibitors, is shown. HCV is believed to ﬁrst intera
concentration of the virion. Subsequently, interaction with other host factors such as SR
mediated endocytosis. For CLDN1 both junctional and non-junctional forms have been de
followed by release of the viral genome into the cytosol where translation and replicatio
alternative route of viral entry is direct cell–cell transmission which is resistant to neutra
at different steps, i.e. viral binding, post-binding and fusion. Ab, antibody; apo, apolipop
sulfate; JAM, junction-associated adhesion molecule; LDLR, low-density lipoprotein r
oligonucleotides; SR-BI, scavenger receptor class B type I; ZO, zona occludens.
Journal of Hepatology 201and HCV infection [80]. In addition, it has been demonstrated that
cell contacts modulate SR-BI and CLDN1 expression levels and
favourHCV internalization through facilitationof entry factor com-
plexes [85]. Further studies are thus necessary to assess which set
of host factors are present with HCV in these complexes.
To date, the sequence of events leading from HCV-interaction
with host factors on the plasma membrane to internalization,
viral fusion, and replication still remains elusive. Studies using
HCVpp and HCVcc have demonstrated that HCV entry into both
hepatoma cells and primary human hepatocytes depends on
clathrin-mediated endocytosis [86–90], the most common routeor antiviral therapies. A model of HCV life cycle, with potential targets for virus
ct with HS and LDLR on the basolateral membrane surface of hepatocytes to allow
-BI, CD81, CLDN1, and OCLN ultimately leads to viral internalization via clathrin-
scribed (for review see [141]). Fusion between viral and endosomal membranes is
n take place. HCV particles are then assembled and released from the host cell. An
lizing antibodies. Entry inhibitors can potentially interfere with the viral life cycle
rotein; BC, bile canaliculi; CLDN1, claudin 1; HCV, hepatitis C virus; HS, heparan
eceptor; nAb, neutralizing antibody; OCLN, occludin; PS-ON, phosphorothioate
1 vol. 54 j 566–576 569
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of endocytosis for viruses that require internalization. Moreover,
actin and clathrin–actin associations have also been shown to be
involved in efﬁcient HCV endocytosis [90]. The question whether
all or part of the plasma membrane expressed HCV host factors
internalize together with HCV still remains unanswered. A recent
study suggests that during internalization, HCV associates with
CD81 and CLDN1 [90]. Moreover, PKA has been suggested to play
a role during this process as inhibition of PKA lead to the reorga-
nization of CLDN1 from the plasma membrane to intracellular
vesicular location(s) and disrupted CD81–CLDN1 co-receptor
association [91]. Interestingly, in line with the fact that polariza-
tion restricts HCV entry [92] and that HCV co-entry factors are
co-expressed on basolateral sites of hepatocytes but not at TJ
[76], imaging studies suggest that HCV internalization does not
preferentially take place at sites of cell–cell contacts [90].
Clathrin-mediated endocytosis transports incoming viruses
together with their receptors into early and late endosomes
[93]. HCVpp have been suggested to be delivered to early but
not late endosomes [87]. This is in line with recent imaging data
showing colocalization between HCV and Rab5a, an early endo-
some marker [90]. The acidic pH in endosomes provides an
essential cue that triggers penetration and uncoating. Penetration
of enveloped virus occurs by membrane fusion catalyzed by
fusion peptides embedded in the viral envelope glycoproteins
[94]. To date, the mechanisms of HCV fusion have not been com-
pletely elucidated but it has been suggested that similar fusion
mechanisms as described for other ﬂaviviridae may apply to
HCV [95–98]. This hypothesis is supported by the observation
that HCVpp entry [8,9,99] and HCVcc infection [86,100] are pH-
dependent, suggesting that a pH-dependent membrane fusion
process may be required for delivery of the HCV genome into
the host cell cytosol. It is worth noting that although HCV entry
requires an acidiﬁcation step, extracellular HCV is resistant to
low pH treatment [87,100]. As HCV fusion kinetics are delayed
as compared to other viruses, it has been suggested that after
internalization, HCVpp entry necessitates additional, low-pH-
dependent interactions, modiﬁcations, or trafﬁcking [87]. How-
ever, neither HCVpp nor HCVcc require cleavage by endosomal
proteases for fusion [87,100]. Several in vitro fusion assays have
been set up in the last years [25,26,49,99]. Liposome/HCVpp
fusion assays suggest that HCVpp-induced fusion was low pH
and temperature-dependent, and facilitated by cholesterol [99].
Interestingly, patient-derived anti-HCV antibodies were able to
inhibit liposome/HCVpp fusion [101] thus highlighting the
importance of HCV envelope glycoproteins in this process. These
data have been recently conﬁrmed in a novel liposome/HCVcc
fusion assay showing that HCVcc fusion was dependent on pH,
lipid composition of both viral and target membranes, and HCV
E2 [102]. However, in this kind of assay no host cell factor is nec-
essary to allow fusion to occur. To study the role of both viral and
host factors in HCV fusion, cell–cell fusion assays have been used
where HCV envelope glycoproteins are expressed on one cell type
and host entry factors on another cell type [25]. Cell–cell fusion
assays are also pH-dependent and most interestingly, these
assays highlighted the importance of CD81 and CLDN1 in this
process [25,49]. To date, it still remains unclear whether these
host factors directly participate in the HCV fusion process or
whether they play a role in an earlier entry step required to
enable efﬁcient subsequent fusion. Taken together, these data
suggest that HCV internalization and fusion offer multiple targets
for the development of HCV entry inhibitors.570 Journal of Hepatology 201An alternative route of entry and spread by cell–cell
transmission
The above described entry mechanisms have been unravelled
using cell-free HCV, i.e. the virus infects surrounding cells after
the formation of viral particles that are released from infected
cells and enter naïve cells by a host factor-dependent mechanism.
In addition, viruses may also use direct cell–cell transfer to infect
neighbouring cells [93] thereby escaping potential interactions
with neutralizing antibodies in the extracellular milieu.
Direct cell–cell transfer or neutralizing antibody-resistant
transmission has been described for HCV [103]. CLDN1, CD81,
and probably SR-BI are involved in this process [85,103]. Interest-
ingly, CD81-independent routes of cell–cell transport have also
been described [103,104]. Direct cell–cell transfer has an impor-
tant impact for the development of antivirals as this process
allows viral spreading by escaping extracellular neutralizing anti-
bodies as well as deﬁned antibodies interfering with host cell
entry factors. It will be challenging to develop novel anti-HCV
therapeutics interfering with this process.
Viral entry offers promising targets for antiviral therapy
In contrast to the current standardof care therapy forHCV infection,
new therapeutic approaches aim at the development of more spe-
ciﬁccompounds targeting thevirus and/orhost cell factors. This rep-
resents the concept of speciﬁcally targeted antiviral therapy forHCV
(STAT-C). This concept consists indevelopingmoreefﬁcientandbet-
ter tolerated combination therapies that need shorter treatment
periods. To date, several small molecular compounds targeting the
HCV non-structural proteins including protease, polymerase, and
NS5Ahavebeendevelopedandareatvariousstagesof clinicaldevel-
opment [1–3,105]. First clinical trial data are promising but toxicity
of the individual compounds and the emergence of resistance
against these drugs limit their use in monotherapy. This suggests
that additional drugs, ideally targeting different steps of the viral life
cycle, are needed for efﬁcient anti-HCV therapy.1 vol. 54 j 566–576
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HCV entry into target cells is a promising target for preventive
and therapeutic antiviral strategies since it is essential for the ini-
tiation, spread, and maintenance of infection. Interfering with
HCV entry holds great promises for drug design and offers several
targets: (i) blocking virus–target cell interaction during attach-
ment and binding, (ii) interfering with post-binding events, and
(iii) interfering with viral fusion (Fig. 1). Various modalities
may be developed as HCV entry inhibitors: these include neutral-
izing antibodies targeting the viral envelope and inhibitory/
blocking antibodies targeting host cell surface factors as well as
small molecule compounds or siRNAs against host cell factors
or viral proteins [106,107].
Several non-HCV speciﬁc molecules interfering with HCV
envelope glycoproteins and abrogating viral attachment have
been described. As HCV envelope proteins are highly glycosyl-
ated, molecules interfering with glycoproteins may possess anti-
viral activity against HCV. As shown for HIV, targeting the glycans
may represent a new therapeutic concept for controlling HCV
infection [108]. Carbohydrate-binding agents that interact with
the viral-envelope glycans may compromise the efﬁcient entry
of the virus into its susceptible target cells and induce a progres-
sive creation of deletions in the envelope glycan shield, thereby
triggering the immune system to act against previously hidden
immunogenic epitopes of the viral envelope [108]. The lectin cya-
novirin-N (CV-N) interacts with high-mannose oligosaccharides
on viral envelope glycoproteins and has been demonstrated to
possess antiviral activity against several enveloped viruses
[109–111]. It has been shown that oligomannose glycans within
the HCV envelope glycoproteins interact with CV-N resulting in
HCV antiviral activity by blocking HCV entry into target cells
[112]. As most of the HCV glycosylation sites are highly con-
served, drugs that target glycans on HCV glycoproteins may not
lead so rapidly to viral escape/resistance as it is the case for
HIV [113]. Other carbohydrate-binding agents that have been
shown to prevent HIV infectivity [108] might also be efﬁcient
against other viruses that require a glycosylated envelope for
entry into target cells. Interfering with the interaction of viral
envelope proteins and glycosaminoglycans on the cell surface is
another way to abrogate viral attachment. HS glycosaminogly-
cans mediate HCV and dengue virus binding to host cells and
heparin, a structural analogue of HS, has been demonstrated to
inhibit dengue virus infection as wells as HCV E2, HCVpp, HCV-
LP, and HCVcc binding to hepatoma cells [34,45,55,114]. HS-like
molecules and semisynthetic derivatives are already explored
as an antiviral approach against dengue virus infection [115].
Such molecules may also have antiviral activity against HCV.
Neutralization of the viral particle may be achieved by target-
ing the HCV envelope or host derived factors associated with the
mature viral particle. The molecular mechanisms of viral assem-
bly and the exact composition of released HCV particles still
remain elusive but recent studies suggest that HCV and VLDL
assembly are closely linked [116,117]. Noteworthy, apolipopro-
tein E (apoE) is required for HCV assembly [118,119] and is also
part of infectious HCV particles [118]. Interestingly, anti-apoE
antibodies are able to inhibit HCV entry [21,118] suggesting that
HCV may be neutralized using compounds directed against the
lipoprotein moiety of the viral particle (Table 1).
Viral attachment and entry is a major target of adaptive host
cell defenses and anti-HCV antibodies represent unique tools to
interfere with the HCV entry process. Virus-speciﬁc neutralizing
antibodies are deﬁned by their antiviral activity enabling themJournal of Hepatology 201to block viral entry and control viral spread. Neutralizing anti-
bodies may interfere with different steps of the viral entry pro-
cess, such as attachment, post-binding steps, and fusion [120].
Two studies of large-scale accidental HCV infections demon-
strated that rapid induction of neutralizing antibodies in the early
phase of infection correlates with viral clearance or control of
infection [36,38]. These studies suggest that neutralizing antibod-
ies represent an interesting approach for the development of
novel preventive and therapeutic antiviral strategies (Table 1).
In line with this concept, it has been shown that immunoglobu-
lins prepared from unscreened donors or from selected patients
with chronic HCV infection have prevented HCV infection in
recipients when administered before exposure to the virus
[6, 121]. Moreover, administration of polyclonal immunoglobu-
lins from a chronically infected patient conveyed sterilizing
immunity toward a homologous strain in human liver-chimeric
Alb-uPA/SCID mouse model [122]. Human mAbs provide an
attractive alternative to polyclonal immune globulin for immuno-
therapy, since mAbs can be more readily standardized. The recent
production of human mAbs efﬁciently cross-neutralizing HCV
may represent an important step for the development of immu-
nopreventive strategies against HCV infection [31,123–125] as
such antibodies have been demonstrated to protect against HCV
quasi-species challenges in vivo in the human liver-chimeric
Alb-uPA/SCID mouse model [31] (Table 1). However, due to the
high variability of HCV, it will be a major challenge to develop
efﬁcient cross-neutralizing antibodies able to target conserved
epitopes across all genotypes to avoid escape. Examples for neu-
tralizing antibodies in preclinical or clinical development are pro-
vided in Table 1.
Targeting the host entry factors, which are indispensable for
the propagation of the virus, represents an additional approach
for the development of antivirals because they may impose a
higher genetic barrier for resistance. HCV interaction with host
entry factors offers multiple targets for the development of spe-
ciﬁc entry inhibitors (Table 1).
CD81 is one of these potential targets. Imidazole based com-
pounds mimicking an alpha helix in the LEL of CD81 compete
for HCV E2–CD81 binding. These drugs bind E2 in a reversible
manner and block E2–CD81 interaction while having no effect
on CD81 expression nor on CD81 interaction with physiological
partner molecules [126]. Interestingly, anti-CD81 antibodies
inhibiting HCV infection in vitro have also been demonstrated
to prevent HCV infection in the human liver-chimeric Alb-uPA/
SCID mouse model [127]. This study suggests that targeting
CD81 may be an efﬁcient strategy to prevent HCV infection
in vivo and demonstrates the proof-of-concept that anti-receptor
antibodies prevent HCV infection in a clinically relevant animal
model.
SR-BI binds a wide variety of molecules and is thus another
interesting target for anti-HCV drugs. SR-BI binds and internal-
izes serum amyloid A (SAA), an acute phase protein produced
in the liver [128,129]. SAA inhibits HCV entry by interacting with
the virus thereby reducing its infectivity [130]. Anti-SR-BI anti-
bodies blocking interaction with HCV are another interesting
strategy to prevent HCV entry. Anti-SR-BI antibodies have been
demonstrated to inhibit HCVcc infection in vitro [66,67,131].
Finally, small molecule inhibitors of SR-BI have recently been
developed. ITX5061 is a compound that inhibits entry of HCVpp
from all major genotypes and HCVcc infection without affecting
viral replication [132]. Kinetic studies suggest that this small1 vol. 54 j 566–576 571
Table 1. Examples of compounds targeting viral entry. Targets within the HCV
entry process are depicted, followed by examples of compounds targeting the
respective entry step. Stages of development and references are indicated. CLDN,
claudin; mAb, monoclonal antibody; pAb, polyclonal antibodies; SR-BI, scavenger
receptor class B type I; PS-ON: phosphorothioate oligonucleotides. (see below-
mentioned reference for further information.)
HCV E1E2
HCV particle
SR-BI
CD81
CLDN1
Internalization/
fusion
Neutralizing antibodies
Heparin and HS analogues
Lectins
Anti-apoE mAb
Anti-SR-BI pAb and mAb
ITX5061
Serum amyloid A
Anti-CD81 mAb
Imidazole based compounds
Anti-CLDN1 pAb and mAb
PS-ON
Arbidol
Chloroquine
Silymarin
Phase II
Phase II
Mouse model
Cell culture
Cell culture
Cell culture
Cell culture
Cell culture
Cell culture
Cell culture
Cell culture
Cell culture
Cell culture
Cell culture
Cell culture
Cell culture
Cell culture
Mouse model
Cell culture
Cell culture
Mouse model
Cell culture
Cell culture
Cell culture
[142]
[143-145]
[31]
[146]
[34, 101, 125]
[33, 147]
[59, 148]
[123]
[124]
[149]
[34, 45, 55]
[112]
[118]
[66, 67, 131]
[132]
[130]
[59, 80, 148] 
[122]
[126]
[78, 133]
[135]
[137, 138]
[86, 100]
[139, 140, 150]
Target ReferencesExamples of compounds Stage of development
Polyclonal HCV IgG (Civacir)
HCV-AbXTL68
Human mAb AR3
CBH and HC antibodies
IGH antibodies
AP33
3/11
Fab e137
mAbs 1:7 and A8
HCV1 and HCV95-2
Reviewmolecule inhibitor targets HCV entry during an early post-bind-
ing stage [132]. The safety of this compound has been evaluated
in patients for another clinical indication [132] allowing future
clinical trials in HCV infected patients.
CLDN1 is a promising antiviral target since it is essential for
HCV entry and to date there is no evidence for CLDN1-indepen-
dent HCV entry. Furthermore, CLDN1 has been suggested to play
an important role in cell–cell transmission. In contrast to other
HCV entry factors such as CD81 or SR-BI, CLDN1 is predominantly
expressed in the liver. Recently, anti-CLDN1 antibodies inhibiting
HCV infection in vitro have been developed [78,133]. Anti-CLDN1
antibodies inhibit HCV infectivity by reducing HCV E2 association
with the cell surface and disrupting CLDN1–CD81 interactions
[78]. Interestingly, monoclonal anti-CLDN1 antibodies efﬁciently
block cell entry of highly infectious escape variants of HCV that
are resistant to host neutralizing antibodies [133]. These data
suggest that anti-CLDN1 antibodies might be used to prevent
HCV infection, such as after LT, and might also restrain virus
spread in chronically infected patients [133].
Finally, OCLN may also be considered as a potential target for
interfering with HCV entry. To date, no anti-OCLN antibodies
inhibiting HCV infection have been described. Further character-
ization of the role of this host cell factor in the HCV entry process
may lead to designing compounds interfering with OCLN and
inhibiting HCV entry.572 Journal of Hepatology 201In addition to cell surface expressed host factors, HCV inter-
nalization and fusion are complex processes that also offer
several targets for antivirals. Long phosphorothioate oligonucleo-
tides (PS-ON) are a promising new class of antiviral compounds.
These amphipathic DNA polymers display a sequence-indepen-
dent antiviral activity against HIV by blocking virus–cell fusion
[134]. A recent study demonstrated that PS-ON inhibited HCV
internalization without affecting viral binding and replication
[135]. A noteworthy observation is that PS-ON block de novo
HCV infection in the human liver-chimeric Alb-uPA/SCID mouse
model [135] highlighting the promise of PS-ON as future clinical
HCV entry inhibitors (Table 1). A peptide-based HIV fusion inhib-
itor (Enfuvirtide) has already been approved for treatment of HIV
infected patients [136]. As HCV fusion requires acidiﬁcation of
the endosome, molecules able to prevent acidiﬁcation of endo-
somes, such as chloroquine, prevent HCV fusion in vitro
[86,100]. In the last few years, other compounds interfering with
HCV fusion have been described (Table 1). Arbidol is a broad-
spectrum antiviral that has already been evaluated in humans
indicating good safety and tolerability (for review see [137]). Arb-
idol inhibits HCV fusion in the HCVpp-liposome assay and pre-
vents HCVpp and HCVcc infection in vitro [137]. In addition,
this molecule also targets other steps of the viral life cycle such
as replication [138]. Silymarin is another compound inhibiting
HCVpp-liposome fusion as well as other steps of the HCV life
cycle, such as replication, protein expression, and infectious virus
production without affecting viral assembly [139,140]. Interest-
ingly, silymarin inhibited HCV infection in vitro irrespective of
the entry route, i.e. cell-free and cell–cell transmission [140],
highlighting the potential of such drugs for in vivo use [141].Conclusions and perspectives
In recent years, substantial progress unravelling the molecular
mechanisms of HCV entry has been made and revealed a multi-
tude of novel targets for antivirals. Several compounds interfering
with HCV entry have been demonstrated to efﬁciently inhibit
HCV infection using in vitro assays or state of the art animal mod-
els and may thus be valuable for future anti-HCV therapy or pre-
vention of HCV infection during LT. As for other chronic viral
infections such as HIV, the future therapeutic and preventive
approach for HCV infection will probably be based on the combi-
nation of several drugs [2,3]. HCV entry inhibitors represent a
promising class of novel antivirals since they are complementary
to current approaches and target an essential step of the viral life
cycle. Indeed, the ﬁrst compounds have reached the early stage of
clinical development. Moreover, recent data suggest that combi-
nation of antivirals targeting the virus and host factors such as
CLDN1 act in an additive manner in suppressing HCV infection
[133]. Thus, combining compounds targeting viral and host cell
factors and complementary steps of the viral life cycle such as
entry and replication is a promising approach for the prevention
of infection in LT and for cure of chronic HCV infection.Conﬂict of interest
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